272 related articles for article (PubMed ID: 16896660)
1. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
[TBL] [Abstract][Full Text] [Related]
3. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Scheiderbauer J; Machulla HJ; Dittmann H; Vonthein R; Bares R
Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):263-9. PubMed ID: 16270214
[TBL] [Abstract][Full Text] [Related]
4. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
[TBL] [Abstract][Full Text] [Related]
5. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
Tönnies S; Bauer TT; Misch D; Boch C; Blum T; Bittner RC; Förster GJ; Kollmeier J
Pneumologie; 2012 Apr; 66(4):212-7. PubMed ID: 22477481
[TBL] [Abstract][Full Text] [Related]
6. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
7. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
Eschmann SM; Friedel G; Paulsen F; Budach W; Harer-Mouline C; Dohmen BM; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555
[TBL] [Abstract][Full Text] [Related]
8. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
[TBL] [Abstract][Full Text] [Related]
9. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
12. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
13. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
Liu SW; Yu JM; Xing LG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
[TBL] [Abstract][Full Text] [Related]
14. The effect of FDG-PET on the stage distribution of non-small cell lung cancer.
Morgensztern D; Goodgame B; Baggstrom MQ; Gao F; Govindan R
J Thorac Oncol; 2008 Feb; 3(2):135-9. PubMed ID: 18303433
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
[TBL] [Abstract][Full Text] [Related]
16. Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management.
Chan SC; Yen TC; Ng SH; Lin CY; Wang HM; Liao CT; Fan KH; Chang JT
J Nucl Med; 2006 Sep; 47(9):1447-54. PubMed ID: 16954552
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of 18-FDG uptake in early stage NSCLC.
Chen JC; Huang TW; Cheng YL; Chang H; Tzao C; Huang WS; Lee SC
Thorac Cardiovasc Surg; 2009 Oct; 57(7):413-6. PubMed ID: 19795329
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
19. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
[TBL] [Abstract][Full Text] [Related]
20. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
Tauhardt E; Reissig A; Winkens T; Freesmeyer M
Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]